(Total Views: 397)
Posted On: 03/31/2020 9:01:00 AM
Post# of 72446
Preliminary Testing Complete on Brilacidin for Coronavirus (Covid-19), Results as Early as Today
March 31, 2020 - As previously disclosed, research is being conducted on Brilacidin as a novel therapeutic against SARS-CoV-2, the coronavirus responsible for Covid-19, at one of the 13 U.S. Regional Biocontainment Laboratories (RBL). The Company was informed late Monday by researchers at the RBL that preliminary testing has been completed and to expect the results as early as today. Subsequently, the results will be released to the public.
We look forward to keeping you apprised of the latest developments in our efforts to fight the Covid-19 pandemic.
Twitter
Facebook
Website
Copyright © 2020 Innovation Pharmaceuticals Inc., All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com
Our mailing address is:
Innovation Pharmaceuticals Inc.
301 Edgewater Pl. Ste 100
Wakefield, MA 01880
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Emails or other types of electronic communication sent or received shall neither constitute acceptance of conducting transactions via electronic means nor create a binding contract until and unless the parties to the contract approve all the terms and sign a written contract.
March 31, 2020 - As previously disclosed, research is being conducted on Brilacidin as a novel therapeutic against SARS-CoV-2, the coronavirus responsible for Covid-19, at one of the 13 U.S. Regional Biocontainment Laboratories (RBL). The Company was informed late Monday by researchers at the RBL that preliminary testing has been completed and to expect the results as early as today. Subsequently, the results will be released to the public.
We look forward to keeping you apprised of the latest developments in our efforts to fight the Covid-19 pandemic.
Website
Copyright © 2020 Innovation Pharmaceuticals Inc., All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com
Our mailing address is:
Innovation Pharmaceuticals Inc.
301 Edgewater Pl. Ste 100
Wakefield, MA 01880
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Emails or other types of electronic communication sent or received shall neither constitute acceptance of conducting transactions via electronic means nor create a binding contract until and unless the parties to the contract approve all the terms and sign a written contract.
(1)
(0)
